CoChat

The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.

PDGF-BB regulates the pulmonary vascular tone: impact of prostaglandins, calcium, MAPK- and PI3K/AKT/mTOR signalling and actin polymerisation in pulmonary veins of guinea pigs

Open access

Abstract

Platelet-derived growth factor (PDGF)-BB and its receptor PDGFR are highly expressed in pulmonary hypertension (PH) and mediate proliferation. Recently, we showed that PDGF-BB contracts pulmonary veins (PVs) and that this contraction is prevented by inhibition of PDGFR-β (imatinib/SU6668). Here, we studied PDGF-BB-induced contraction and downstream-signalling in isolated perfused lungs (IPL) and precision-cut lung slices (PCLS) of guinea pigs (GPs). In IPLs, PDGF-BB was perfused after or without pre-treatment with imatinib (perfused/nebulised), the effects on the pulmonary arterial pressure (P PA ), the left atrial pressure (P LA ) and the capillary pressure (P cap ) were studied and the precapillary (R pre ) and postcapillary resistance (R post ) were calculated. Perfusate samples were analysed (ELISA) to detect the PDGF-BB-induced release of prostaglandin metabolites (TXA 2 /PGI 2 ). In PCLS, the contractile effect of PDGF-BB was evaluated in pulmonary arteries (PAs) and PVs. In PVs, PDGF-BB-induced contraction was studied after inhibition of PDGFR-α/β, L-Type Ca 2+ -channels, ROCK/PKC, prostaglandin receptors, MAP2K, p38-MAPK, PI3K-α/γ, AKT/PKB, actin polymerisation, adenyl cyclase and NO. Changes of the vascular tone were measured by videomicroscopy. In PVs, intracellular cAMP was measured by ELISA. In IPLs, PDGF-BB increased P PA , P cap and R post . In contrast, PDGF-BB had no effect if lungs were pre-treated with imatinib (perfused/nebulised). In PCLS, PDGF-BB significantly contracted PVs/PAs which was blocked by the PDGFR-β antagonist SU6668. In PVs, inhibition of actin polymerisation and inhibition of L-Type Ca 2+ -channels reduced PDGF-BB-induced contraction, whereas inhibition of ROCK/PKC had no effect. Blocking of EP 1/3 - and TP-receptors or inhibition of MAP2K-, p38-MAPK-, PI3K-α/γ- and AKT/PKB-signalling prevented PDGF-BB-induced contraction, whereas inhibition of EP 4 only slightly reduced it. Accordingly, PDGF-BB increased TXA 2 in the perfusate, whereas PGI 2 was increased in all groups after 120 min and inhibition of IP-receptors did not enhance PDGF-BB-induced contraction. Moreover, PDGF-BB increased cAMP in PVs and inhibition of adenyl cyclase enhanced PDGF-BB-induced contraction, whereas inhibition of NO-formation only slightly increased it. PDGF-BB/PDGFR regulates the pulmonary vascular tone by the generation of prostaglandins, the increase of calcium, the activation of MAPK- or PI3K/AKT/mTOR signalling and actin remodelling. More insights in PDGF-BB downstream-signalling may contribute to develop new therapeutics for PH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12931-018-0829-5

Cites

138 of 138 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Overview of the timeline. This overview illustrates the different groups and the timeline of all experiments using the IPL
Fig. 1 Overview of the timeline. This overview illustrates the different groups and the timeline of all experiments using the IPLCC BY · PubMed Central
Fig. 2 IPL: Effect of PDGF-BB on the pulmonary vascular tone. a Effect of PDGF-BB on PPA. b Effect of PDGF-BB on Pcap. c Effect of PDGF-BB on Rpre. d Effect of PDGF-BB on Rpost. For all: (○) control (n = 7); (■) PDGF-BB (n = 7); (grey circle) imatinib (n = 7); (grey square) perfused imatinib / PDGF-BB (n = 7); (□) nebulised imatinib / PDGF-BB (n = 6); a-d Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001. a grey square / grey circle Time point 0 (§) vs. 140 (§§) min: p < 0.001. d grey circle Time point 0 (§) vs. 140 (§§) min: p < 0.05
Fig. 2 IPL: Effect of PDGF-BB on the pulmonary vascular tone. a Effect of PDGF-BB on PPA. b Effect of PDGF-BB on Pcap. c Effect of PDGF-BB on Rpre. d Effect of PDGF-BB on Rpost. For all: (○) control (n = 7); (■) PDGF-BB (n = 7); (grey circle) imatinib (n = 7); (grey square) perfused imatinib / PDGF-BB (n = 7); (□) nebulised imatinib / PDGF-BB (n = 6); a-d Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001. a grey square / grey circle Time point 0 (§) vs. 140 (§§) min: p < 0.001. d grey circle Time point 0 (§) vs. 140 (§§) min: p < 0.05CC BY · PubMed Central
Fig. 3 PCLS: PDGF-BB contracts PAs and PVs via activation of PDGFR-β. a PDGF-BB contracts PVs: (■) no pre-treatment / 100 nM PDGF-BB (n = 7); (grey square) 100 nM ponatinib / 100 nM PDGF-BB (n = 7); (□) 5 μM SU6668 / 100 nM PDGF-BB (n = 7). b The contractile effect of PDGF-BB in PAs: (●) no pre-treatment / 100 nM PDGF-BB (n = 7); (grey circle) 100 nM ponatinib / 100 nM PDGF-BB (n = 7); (○) 5 μM SU6668 / 100 nM PDGF-BB (n = 7). c PDGF-BB-induced contraction in PAs/PVs: (●) PAs: 100 nM PDGF-BB (n = 7); (■) PVs: 100 nM PDGF-BB (n = 7). a-c Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001
Fig. 3 PCLS: PDGF-BB contracts PAs and PVs via activation of PDGFR-β. a PDGF-BB contracts PVs: (■) no pre-treatment / 100 nM PDGF-BB (n = 7); (grey square) 100 nM ponatinib / 100 nM PDGF-BB (n = 7); (□) 5 μM SU6668 / 100 nM PDGF-BB (n = 7). b The contractile effect of PDGF-BB in PAs: (●) no pre-treatment / 100 nM PDGF-BB (n = 7); (grey circle) 100 nM ponatinib / 100 nM PDGF-BB (n = 7); (○) 5 μM SU6668 / 100 nM PDGF-BB (n = 7). c PDGF-BB-induced contraction in PAs/PVs: (●) PAs: 100 nM PDGF-BB (n = 7); (■) PVs: 100 nM PDGF-BB (n = 7). a-c Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001CC BY · PubMed Central
Fig. 4 PCLS: The role of Ca2+ in PDGF-BB-induced contraction in PVs. a PDGF-BB-induced contraction depends on the activation of L-Type Ca2+-channels: (■) no pre-treatment / 100 nM PDGF-BB (n = 8); (□) 100 nM amlodipine / 100 nM PDGF-BB (n = 8). b PDGF-BB-induced contraction does not depend on the activation of Rho Kinase: (■) no pre-treatment / 100 nM PDGF-BB (n = 8); (□) 10 μM fasudile / 100 nM PDGF-BB (n = 8). C) PDGF-BB-induced contraction does not depend on the activation of protein kinase C (PKC): (■) no pre-treatment / 100 nM PDGF-BB (n = 8); (□) 5 μM calphostin C / 100 nM PDGF-BB (n = 8). a-c Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001
Fig. 4 PCLS: The role of Ca2+ in PDGF-BB-induced contraction in PVs. a PDGF-BB-induced contraction depends on the activation of L-Type Ca2+-channels: (■) no pre-treatment / 100 nM PDGF-BB (n = 8); (□) 100 nM amlodipine / 100 nM PDGF-BB (n = 8). b PDGF-BB-induced contraction does not depend on the activation of Rho Kinase: (■) no pre-treatment / 100 nM PDGF-BB (n = 8); (□) 10 μM fasudile / 100 nM PDGF-BB (n = 8). C) PDGF-BB-induced contraction does not depend on the activation of protein kinase C (PKC): (■) no pre-treatment / 100 nM PDGF-BB (n = 8); (□) 5 μM calphostin C / 100 nM PDGF-BB (n = 8). a-c Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001CC BY · PubMed Central
Fig. 5 PCLS: The role of prostaglandins in PDGF-BB-induced contraction in PVs. a Effect of inhibited cyclooxygenase on PDGF-BB-induced contraction: (■) no pre-treatment / 100 nM PDGF-BB (n = 8); (□) 3 μM indomethacin / 100 nM PDGF-BB (n = 8). b PDGF-BB-induced contraction is mediated via EP1/3-receptors: (■) no pre-treatment / 100 nM PDGF-BB (n = 8); (□) 1 μM SC51322 (EP1) / 100 nM PDGF-BB (n = 8); (grey square) 1 μM L798106 (EP3) / 100 nM PDGF-BB (n = 7). c PDGF-BB-induced contraction does not depend on EP2-receptors: (■) no pre-treatment / 100 nM PDGF-BB (n = 5); (□) 1 μM PF04418948 / 100 nM PDGF-BB (n = 5). d PDGF-BB-induced contraction depends on EP4-receptors: (■) no pre-treatment / 100 nM PDGF-BB (n = 5); (□) 1 μM L161982 / 100 nM PDGF-BB (n = 5). e PDGF-BB-induced contraction depends on TP-receptors: (■) no pre-treatment / 100 nM PDGF-BB (n = 7); (□) 10 μM SQ29548 / 100 nM PDGF-BB (n = 7). f PDGF-BB-induced contraction does not depend on IP-receptors: (■) no pre-treatment / 100 nM PDGF-BB (n = 4); (□) 1 μM RO-1138452 / 100 nM PDGF-BB (n = 4). a-f Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 or *** p < 0.001
Fig. 5 PCLS: The role of prostaglandins in PDGF-BB-induced contraction in PVs. a Effect of inhibited cyclooxygenase on PDGF-BB-induced contraction: (■) no pre-treatment / 100 nM PDGF-BB (n = 8); (□) 3 μM indomethacin / 100 nM PDGF-BB (n = 8). b PDGF-BB-induced contraction is mediated via EP1/3-receptors: (■) no pre-treatment / 100 nM PDGF-BB (n = 8); (□) 1 μM SC51322 (EP1) / 100 nM PDGF-BB (n = 8); (grey square) 1 μM L798106 (EP3) / 100 nM PDGF-BB (n = 7). c PDGF-BB-induced contraction does not depend on EP2-receptors: (■) no pre-treatment / 100 nM PDGF-BB (n = 5); (□) 1 μM PF04418948 / 100 nM PDGF-BB (n = 5). d PDGF-BB-induced contraction depends on EP4-receptors: (■) no pre-treatment / 100 nM PDGF-BB (n = 5); (□) 1 μM L161982 / 100 nM PDGF-BB (n = 5). e PDGF-BB-induced contraction depends on TP-receptors: (■) no pre-treatment / 100 nM PDGF-BB (n = 7); (□) 10 μM SQ29548 / 100 nM PDGF-BB (n = 7). f PDGF-BB-induced contraction does not depend on IP-receptors: (■) no pre-treatment / 100 nM PDGF-BB (n = 4); (□) 1 μM RO-1138452 / 100 nM PDGF-BB (n = 4). a-f Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 or *** p < 0.001CC BY · PubMed Central
Fig. 6 The effect of PDGF-BB on TXB2 and 6-keto PGF1α. a TXB2-generation in dependence of the perfusion time. b Comparison of TXB2-generation within the groups at the same time. c 6-keto PGF1α-generation in dependence of the perfusion time. d Comparison of 6-keto PGF1α-generation within the groups at the same time. For all (□) control (n = 6); (■) perfusion with PDGF-BB (n = 6); (grey square) perfusion with imatinib / PDGF-BB (n = 6); (□) perfusion with imatinib (n = 6). a/c Statistics was performed by the Wilcoxon signed ranked test. b/d Statistics was performed by the Mann-Whitney U test. P < 0.05 are considered as significant: * p < 0.05 and ** p < 0.01
Fig. 6 The effect of PDGF-BB on TXB2 and 6-keto PGF1α. a TXB2-generation in dependence of the perfusion time. b Comparison of TXB2-generation within the groups at the same time. c 6-keto PGF1α-generation in dependence of the perfusion time. d Comparison of 6-keto PGF1α-generation within the groups at the same time. For all (□) control (n = 6); (■) perfusion with PDGF-BB (n = 6); (grey square) perfusion with imatinib / PDGF-BB (n = 6); (□) perfusion with imatinib (n = 6). a/c Statistics was performed by the Wilcoxon signed ranked test. b/d Statistics was performed by the Mann-Whitney U test. P < 0.05 are considered as significant: * p < 0.05 and ** p < 0.01CC BY · PubMed Central
Fig. 7 PCLS: PDGFR downstream-signalling: MAPK- and PI3K/AKT/PKB-pathway in PVs. a PDGF-BB-induced contraction depends on MAP2K: (■) no pre-treatment / 100 nM PDGF-BB (n = 4); (□) 50 μM PD98059 / 100 nM PDGF-BB (n = 4); (grey square) 5 μM U0126 / 100 nM PDGF-BB (n = 4). b PDGF-BB-induced contraction depends on p-38/MAPK: (■) no pre-treatment / 100 nM PDGF-BB (n = 4); (□) 5 μM SB203580 / 100 nM PDGF-BB (n = 4). c PDGF-BB-induced contraction is mediated via PI3K-α: (■) no pre-treatment / 100 nM PDGF-BB (n = 6); (□) 1 μM GSK 1059625 / 100 nM PDGF-BB (n = 6). d PDGF-BB-induced contraction does not interact with PI3K-γ: (■) no pre-treatment / 100 nM PDGF-BB (n = 5); (□) 1 μM AS252424 / 100 nM PDGF-BB (n = 5). e PDGF-BB-induced contraction depends on the AKT/PKB signalling: (■) no pre-treatment / 100 nM PDGF-BB (n = 4); (□ 10 μM 10-DEBC / 100 nM PDGF-BB (n = 4). a-e) Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001
Fig. 7 PCLS: PDGFR downstream-signalling: MAPK- and PI3K/AKT/PKB-pathway in PVs. a PDGF-BB-induced contraction depends on MAP2K: (■) no pre-treatment / 100 nM PDGF-BB (n = 4); (□) 50 μM PD98059 / 100 nM PDGF-BB (n = 4); (grey square) 5 μM U0126 / 100 nM PDGF-BB (n = 4). b PDGF-BB-induced contraction depends on p-38/MAPK: (■) no pre-treatment / 100 nM PDGF-BB (n = 4); (□) 5 μM SB203580 / 100 nM PDGF-BB (n = 4). c PDGF-BB-induced contraction is mediated via PI3K-α: (■) no pre-treatment / 100 nM PDGF-BB (n = 6); (□) 1 μM GSK 1059625 / 100 nM PDGF-BB (n = 6). d PDGF-BB-induced contraction does not interact with PI3K-γ: (■) no pre-treatment / 100 nM PDGF-BB (n = 5); (□) 1 μM AS252424 / 100 nM PDGF-BB (n = 5). e PDGF-BB-induced contraction depends on the AKT/PKB signalling: (■) no pre-treatment / 100 nM PDGF-BB (n = 4); (□ 10 μM 10-DEBC / 100 nM PDGF-BB (n = 4). a-e) Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001CC BY · PubMed Central
Fig. 8 Relevance of relaxant signalling cascades in PDGFR-signalling in PVs. a Role of cAMP in PDGFR-signalling: (■) no pre-treatment / 100 nM PDGF-BB (n = 10); (grey square) 100 μM SQ22536 / 100 nM PDGF-BB (n = 10). b Role of NO in PDGFR-signalling: (■) no pre-treatment / 100 nM PDGF-BB (n = 10); (grey square) 100 μM L-NAME / 100 nM PDGF-BB (n = 10). c PDGF-BB increases intracellular cAMP: (□) no PDGF-BB (control) (n = 10); (■) 100 nM PDGF-BB (n = 11) a/b Statistics was performed by a LMM. C) Statistics was performed by the Mann-Whitney U test. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001
Fig. 8 Relevance of relaxant signalling cascades in PDGFR-signalling in PVs. a Role of cAMP in PDGFR-signalling: (■) no pre-treatment / 100 nM PDGF-BB (n = 10); (grey square) 100 μM SQ22536 / 100 nM PDGF-BB (n = 10). b Role of NO in PDGFR-signalling: (■) no pre-treatment / 100 nM PDGF-BB (n = 10); (grey square) 100 μM L-NAME / 100 nM PDGF-BB (n = 10). c PDGF-BB increases intracellular cAMP: (□) no PDGF-BB (control) (n = 10); (■) 100 nM PDGF-BB (n = 11) a/b Statistics was performed by a LMM. C) Statistics was performed by the Mann-Whitney U test. P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001CC BY · PubMed Central
Fig. 9 The role of actin polymerisation in PDGF-BB-induced contraction. a. Inhibition of actin polymerisation by cytochalasin D: (■) no pre-treatment / 100 nM PDGF-B (n = 4); (□) 10 μM cytochalasin D / 100 nM PDGF-BB (n = 4). b Inhibition of actin polymerisation by latrunculin A: (■) no pre-treatment / 100 nM PDGF-BB (n = 4); (□) 1 μM latrunculin A / 100 nM PDGF-BB (n = 4). a/b Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05 and *** p < 0.001
Fig. 9 The role of actin polymerisation in PDGF-BB-induced contraction. a. Inhibition of actin polymerisation by cytochalasin D: (■) no pre-treatment / 100 nM PDGF-B (n = 4); (□) 10 μM cytochalasin D / 100 nM PDGF-BB (n = 4). b Inhibition of actin polymerisation by latrunculin A: (■) no pre-treatment / 100 nM PDGF-BB (n = 4); (□) 1 μM latrunculin A / 100 nM PDGF-BB (n = 4). a/b Statistics was performed by a LMM. P < 0.05 are considered as significant: * p < 0.05 and *** p < 0.001CC BY · PubMed Central
Fig. 10 Complex involvement of prostaglandins within the contractile effect of PDGF-BB. The contractile effect of PDGF-BB depends on the activation of L-Type Ca2+-channels and on calcium [9, 10, 64], promoting the activation of myosin light chain kinase (MLCK) and vascular SMC contraction [24]. Increased intracellular calcium-levels activate cPLA2 [19] leading to the formation of arachidonic acid (AA) [131]. Cytosolic PLA2 is also activated by MAP2K−/p-38-MAPK-signalling [71, 103], whereas PI3K- or AKT-signalling prevent its degradation [107]. AA serves as a substrate for the production of prostaglandins e.g. PGE2 or TXA2 [132] which bind to EP- or TP-receptors. EP1/3- or TP-receptors are mainly coupled to Gαq/11, leading to the formation of IP3 and to the release of calcium from the sarcoplasmic reticulum (SR) [25, 88]. TP-receptors are also linked to Gβγ activating MAPK-signalling [80]. Further, TP-receptors are coupled to Gα12/13 [25, 88] activating Rho/ROCK and inhibiting myosin light chain phosphatase (MLCP) [24]. Vascular SMC contraction is further enhanced, if PKC inhibits MLCP [24]. Beyond Gαq/11, EP3-receptors are coupled to Gαi inhibiting cAMP-generation, whereas EP4-receptors are coupled to Gαs, promoting cAMP-generation [25]. Cyclic AMP induces the formation of protein kinase A (PKA) which inhibits MLCK [23] and activates MLCP [133]. The role of PGI2 and IP-receptor-activation is less relevant within PDGFR-downstream signalling, but is not completely solved. PDGFR-signalling also activates AKT/PKB [101] which stimulates eNOS [108]. Last, transactivation of AT1-receptors and PDGFR [101] is described leading to the increase of calcium [134]. The dashed line indicates pathways which are in contrast to our results
Fig. 10 Complex involvement of prostaglandins within the contractile effect of PDGF-BB. The contractile effect of PDGF-BB depends on the activation of L-Type Ca2+-channels and on calcium [9, 10, 64], promoting the activation of myosin light chain kinase (MLCK) and vascular SMC contraction [24]. Increased intracellular calcium-levels activate cPLA2 [19] leading to the formation of arachidonic acid (AA) [131]. Cytosolic PLA2 is also activated by MAP2K−/p-38-MAPK-signalling [71, 103], whereas PI3K- or AKT-signalling prevent its degradation [107]. AA serves as a substrate for the production of prostaglandins e.g. PGE2 or TXA2 [132] which bind to EP- or TP-receptors. EP1/3- or TP-receptors are mainly coupled to Gαq/11, leading to the formation of IP3 and to the release of calcium from the sarcoplasmic reticulum (SR) [25, 88]. TP-receptors are also linked to Gβγ activating MAPK-signalling [80]. Further, TP-receptors are coupled to Gα12/13 [25, 88] activating Rho/ROCK and inhibiting myosin light chain phosphatase (MLCP) [24]. Vascular SMC contraction is further enhanced, if PKC inhibits MLCP [24]. Beyond Gαq/11, EP3-receptors are coupled to Gαi inhibiting cAMP-generation, whereas EP4-receptors are coupled to Gαs, promoting cAMP-generation [25]. Cyclic AMP induces the formation of protein kinase A (PKA) which inhibits MLCK [23] and activates MLCP [133]. The role of PGI2 and IP-receptor-activation is less relevant within PDGFR-downstream signalling, but is not completely solved. PDGFR-signalling also activates AKT/PKB [101] which stimulates eNOS [108]. Last, transactivation of AT1-receptors and PDGFR [101] is described leading to the increase of calcium [134]. The dashed line indicates pathways which are in contrast to our resultsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 138 references

Cited by

See all 59

Metadata

Authors
Rieg, A. D., Suleiman, S., Anker, C., Verjans, E., Rossaint, R., Uhlig, S., & Martin, C.
Affiliations
RWTH Aachen University (DE)
Corresponding author
Rieg, Annette D.
Venue
Respiratory Research
Published
2018-06-19
Volume
19
Issue
1
Pages
120-120
ISSN
  • 1465-9921 (ISSN-L)
  • 1465-993X
OpenAlex
W2809056942
Cited by
59
References
136
Citations by year
2026: 5 · 2025: 10 · 2024: 8 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 7 · 2018: 2
FWCI
4.14
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Respiratory Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RWTH Publications (RWTH Aachen) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • RWTH Publications (RWTH Aachen)
Funders
RWTH Aachen University (109/14 (691440))
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Surgery › Cardiovascular, Neuropeptides, and Oxidative Stress Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
PDGF-BB, pulmonary vascular tone, pulmonary hypertension, pulmonary veins, pulmonary artery, imatinib, SU6668, PDGFRβ, prostaglandins, thromboxane A2, prostacyclin, L-type calcium channels, actin polymerization, p38 MAPK, PI3K/AKT/mTOR signalling, cAMP signaling
MeSH terms
Becaplermin, Phosphoinositide-3 Kinase Inhibitors, Actins, Animals, Calcium, Female, Guinea Pigs, Prostaglandins, Pulmonary Veins, Vasomotor System, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-sis, MAP Kinase Signaling System, Angiogenesis Inducing Agents, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Polymerization, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PDGF-BB regulates the pulmonary vascular tone: impact of prostaglandins, calcium, MAPK- and PI3K/AKT/mTOR signalling and actin polymerisation in pulmonary veins of guinea pigs. https://app.cochat.ai/papers/10.1186/s12931-018-0829-5
The paper
Rieg, A. D., Suleiman, S., Anker, C., Verjans, E., Rossaint, R., Uhlig, S., & Martin, C. (2018). PDGF-BB regulates the pulmonary vascular tone: impact of prostaglandins, calcium, MAPK- and PI3K/AKT/mTOR signalling and actin polymerisation in pulmonary veins of guinea pigs. Respiratory Research. https://doi.org/10.1186/s12931-018-0829-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.